Tag - CytoAgents

Pittsburgh biotech company wins funding for Covid-19 drug

Pittsburgh biotech company CytoAgents has received $250,000 from the Richard King Mellon Foundation to help develop its drug candidate to treat cytokine storm, a deadly complication of Covid-19 and other upper respiratory illnesses. CytoAgents has been working on phase I and phase II clinical trials for GP1681, its existing drug candidate that even before Covid-19 had treated the immune response that causes inflammation and respiratory distress for people with severe influenza. It received a $1.6 million grant from the […]